Disease Landscape and Forecast Insights

MARKET OUTLOOK In the past decade, AbbVie’s Humira and Amgen’s Enbrel tumor necrosis factor-alpha (TNF-α) inhibitors and Janssen’s interleukin (IL)-12/23 inhibitor Stelara have been…

TNF-α inhibitors are well entrenched in the U.S. ulcerative colitis (UC) and Crohn’s disease (CD) markets. Newer biologics that offer alternative treatment options (i.e., Takeda’s Entyvio and…

Payers play a significant role in defining the commercial success of biosimilars—as well as their reference brands—as they decide which products are granted formulary access and preferential…

MARKET OUTLOOK Rheumatoid arthritis (RA) is a chronic and progressive autoimmune disease that primarily affects the joints. China has globally the highest number of RA patients, and the Chinese…

MARKET OUTLOOK The treatment landscape for psoriasis in the top 5 European markets (France, Germany, Italy, Spain, UK) is extremely dynamic. Humira (AbbVie), Enbrel (Amgen), Stelara (Janssen), and…

The regulatory and market access landscape for biosimilars is constantly evolving. For a company seeking to develop a biosimilar for multiple markets, keeping track of the similarities and…

Market OutlookClinical pathways, which establish optimal treatment protocols for specific patient populations based on the best evidence, have become increasingly prevalent in the treatment of…

MARKET OUTLOOK The introduction of additional Crohn’s disease (CD) agents has shifted—and will continue to shift—market dynamics. The newer non-TNF biologics (Takeda’s Entyvio and…

With the availability of multiple approved products for the treatment of diabetic macular edema (DME) in the EU5, including Bayer HealthCare’s Eylea, Novartis’s Lucentis, Allergan’s Ozurdex,…

Payers play a significant role in defining the commercial success of biosimilars—as well as their reference brands—as they decide which products are granted formulary access and preferential…

Vascular endothelial growth factor (VEGF) inhibitors—approved agents Eylea (Regeneron) and Lucentis (Roche/Genentech), and off-label Avastin (Roche/Genentech)—are the treatment mainstays for…

The regulatory and market access landscape for biosimilars is constantly evolving. For a company seeking to develop a biosimilar for multiple markets, keeping track of the similarities and…